Aura Biosciences, Inc. (NASDAQ:AURA) Shares Purchased by Franklin Resources Inc.

Franklin Resources Inc. raised its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,723,063 shares of the company's stock after acquiring an additional 54,103 shares during the quarter. Franklin Resources Inc. owned approximately 3.45% of Aura Biosciences worth $14,164,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. grew its holdings in shares of Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock valued at $1,233,000 after purchasing an additional 3,612 shares in the last quarter. State Street Corp grew its stake in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company's stock worth $6,725,000 after acquiring an additional 26,841 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Aura Biosciences during the third quarter worth $1,037,000. Barclays PLC raised its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after acquiring an additional 43,897 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after purchasing an additional 39,379 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. JMP Securities set a $19.00 price target on Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 target price on shares of Aura Biosciences in a report on Tuesday, March 25th. Citigroup reiterated an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Finally, Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Aura Biosciences has a consensus rating of "Buy" and a consensus price target of $22.75.

Aura Biosciences Stock Performance

AURA stock traded up $0.33 during midday trading on Friday, reaching $5.30. 195,986 shares of the company were exchanged, compared to its average volume of 199,817. The company has a market cap of $266.19 million, a price-to-earnings ratio of -3.06 and a beta of 0.43. Aura Biosciences, Inc. has a 1-year low of $4.84 and a 1-year high of $12.38. The stock's 50-day simple moving average is $6.96 and its 200 day simple moving average is $8.28.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09). On average, research analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current year.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares of the company's stock, valued at approximately $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 23,045 shares of company stock worth $177,242. Corporate insiders own 5.40% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.